This page shows the latest vaccines news and features for those working in and with pharma, biotech and healthcare.
weeks. This recommendation was based on a study that showed that extending the time between doses improves the efficacy of the vaccine. ... This is good news for older people who are waiting for a vaccine.
The UK Vaccines Taskforce is also working with CureVac to assess multiple variants of the SARS-CoV-2 virus that causes COVID-19, and will seek to generate vaccine candidates against ... In a statement, the UK government said that ‘almost all
8%. The results also suggested the vaccine was 100% effective in preventing severe COVID-19.. ... It will assess all available data for the vaccine until it has enough for a formal marketing authorisation application.
This includes providing ‘robust’ evidence that a modified vaccine produces an immune response against a COVID-19 variant. ... A number of vaccine makers are working on modified vaccines to address new and emerging variants.
In January, Novavax published results from the UK trial, which demonstrated a vaccine efficacy rate of 89.3%. ... Erck added that Novavax could begin shipping the COVID-19 vaccine to the US in June or July.
AstraZeneca (AZ) has announced the first doses of its Oxford University-partnered COVID-19 vaccine have begun arriving in low and middle-income countries through the international vaccines-sharing facility COVAX. ... accelerate development, production
More from news
Approximately 160 fully matching, plus 1,319 partially matching documents found.
But while unprecedented feats were achieved in clinical research for COVID-19 treatments and vaccines, many other projects were halted and patient recruitment stopped entirely. ... By contrast, the discovery and development of multiple successful
molecules – such as the spike proteins on the COVID-19 virus – and accelerate drug and vaccine discovery. ... to solve large-scale problems and improve patient care, diagnosis and delivery of critical medicines and vaccines.
potentially life-saving medicines, a vaccine for COVID-19 being a prime example. ... motion. Many doubted that an effective vaccine for COVID-19 could be developed and approved for use by the end of 2020, yet here we are.
There is also a warm glow around the pharmaceutical and healthcare sectors created by the astonishing speed of vaccine R&D and delivery, and Young added: “There is incredible pride in
to be differentiated as part of any vaccine-based track-and-trace effort. ... And in 2021, the ability to trace where vaccines and COVID-19- linked treatments have ended up will be critical.
More from intelligence
Approximately 6 fully matching, plus 121 partially matching documents found.
Over the course of his most recent stint at Merck, the company has achieved over 100 regulatory approvals for its medicines and vaccines globally. ... As a result of Roger’s hands-on and inspirational leadership, MRL is well positioned to bring forward
In his new role, he will become a member of the firm’s senior management team, and will continue to oversee key client engagements in infectious diseases, vaccines and immuno-oncology.
Most recently, she held the position of vice president of M&A operations and divestitures and led the infectious diseases and vaccines business development. ... She joins Eisai from Merck, where she served as executive director, clinical quality assurance
He has also been a member of the corporate executive team for GlaxoSmithKline and chief executive officer of GSK Biologicals (now GSK Vaccines).
Dr Carucci has over 25 years of experience in large-scale innovation programs, vaccine development, organisational leadership, and global public health, during which time he served as VP for global health
More from appointments
Approximately 5 fully matching, plus 64 partially matching documents found.
Whilst we might have been dubbed ‘Plague Island’ by some, we’re now –thanks to the vaccines – more of a speedboat than a tanker. ... Or if you’re a shark that’s been hunted for its liver oil or ‘squalene’, also used in vaccine production
Unline many sectors, healthcare is uniquely challenged by COVID - the race to develop vaccines being one example.
The HeLa cell line has been used across countless ground-breaking medical discoveries and advancements, including the polio vaccine, gene mapping, cancer research, the list goes on.
August. Lofty goals at a time when even distributing the vaccines is a logistical challenge. But perhaps the biggest challenge is getting people to have the vaccine at all. Consider the ... the vaccines work, how safety is monitored, what new
1. The vaccine roll out in the EU markets is proving to have a lot of grit in the system, from approvals and licensing, to pricing challenges, to logistics. ... The vaccine developers are staying on top of the mutant strains and getting just
More from PMHub
Approximately 10 fully matching, plus 71 partially matching documents found.
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...